Allogene Therapeutics, Inc. - stock earnings
ALLO Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 BeforeMarket | - / -0.3900000000 | - | - / 20000 | - |
ALLO Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -85.8 million USD | 21000 USD |
| 2023Q3 | -61.3 million USD | 43000 USD |
| 2023Q2 | -78.0 million USD | 44000 USD |
| 2023Q1 | -98.3 million USD | 52000 USD |
| 2022Q4 | -93.3 million USD | 47000 USD |
| 2022Q3 | -82.1 million USD | 49000 USD |
| 2022Q2 | -74.5 million USD | 86000 USD |
| 2022Q1 | -79.7 million USD | 61000 USD |
| 2021Q4 | -74.9 million USD | 51000 USD |
| 2021Q3 | -78.2 million USD | 49000 USD |
| 2021Q2 | -70.9 million USD | 44000 USD |
| 2021Q1 | -33.0 million USD | 38.3 million USD |
| 2020Q4 | -68.6 million USD | ? USD |
| 2020Q3 | -66.2 million USD | ? USD |
| 2020Q2 | -61.0 million USD | ? USD |
| 2020Q1 | -54.5 million USD | ? USD |
| 2019Q4 | -61.0 million USD | ? USD |
| 2019Q3 | -50.7 million USD | ? USD |
| 2019Q2 | -41.2 million USD | ? USD |
| 2019Q1 | -31.6 million USD | ? USD |
| 2018Q4 | -30.5 million USD | ? USD |
| 2018Q3 | -43.5 million USD | ? USD |
| 2018Q2 | -134.9 million USD | ? USD |
| 2018Q1 | -2.6 million USD | ? USD |
| 2017Q4 | -2000 USD | ? USD |
ALLO Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -327.3 million USD | 95000 USD |
| 2022 | -329.8 million USD | 243000 USD |
| 2021 | -244.8 million USD | 38.5 million USD |
| 2020 | -233.5 million USD | 38.3 million USD |
| 2019 | -184.6 million USD | ? USD |
| 2018 | -211.5 million USD | ? USD |
| 2017 | -2000 USD | ? USD |
ALLO
Price: $2.89
52 week price:
Earnings Per Share: -2.09 USD
P/E Ratio: -2.10
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 358933
Market Capitalization: 674.7 million